VERTEX PHARMACEUTICALS INC / MA Net Income (Loss) Available to Common Stockholders, Diluted
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Net Income (Loss) Available to Common Stockholders, Diluted of $2.71 billion for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA net income (loss) available to common stockholders, diluted for the quarter ending 2019-12-31 was $583.23M, a 62.38% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) available to common stockholders, diluted for the quarter ending 2019-09-30 was $57.52M, a 55.32% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) available to common stockholders, diluted for the quarter ending 2019-06-30 was $267.43M, a 29.01% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) available to common stockholders, diluted for the quarter ending 2019-03-31 was $268.63M, a 27.82% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) available to common stockholders, diluted for fiscal 2020 was $2.71B, a 130.42% increase from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) available to common stockholders, diluted for fiscal 2019 was $1.18B, a 43.87% decline from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) available to common stockholders, diluted for fiscal 2018 was $2.10B, a 696.52% increase from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA net income (loss) available to common stockholders, diluted for fiscal 2017 was $263.20M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $2.71B 10-K · filed 2021-02-11 | ||||
| 2019-12-31 | $583.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $640.75M derived: sum of 2 quarters · filed 2021-02-11 | $908.18M derived: sum of 3 quarters · filed 2021-02-11 | $1.18B 10-K · filed 2021-02-11 | |
| 2019-09-30 | $57.52M 10-Q · filed 2019-10-31 | $324.94M derived: sum of 2 quarters · filed 2019-10-31 | $593.58M 10-Q · filed 2019-10-31 | $2.14B derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-06-30 | $267.43M 10-Q · filed 2019-08-01 | $536.06M 10-Q · filed 2019-08-01 | $2.09B derived: sum of 3 quarters · filed 2021-02-11 | $2.21B derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-03-31 | $268.63M 10-Q · filed 2019-05-01 | $1.82B derived: sum of 2 quarters · filed 2021-02-11 | $1.95B derived: sum of 3 quarters · filed 2021-02-11 | $2.15B derived: sum of 4 quarters · filed 2021-02-11 | |
| 2018-12-31 | $1.55B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $1.68B derived: sum of 2 quarters · filed 2021-02-11 | $1.89B derived: sum of 3 quarters · filed 2021-02-11 | $2.10B 10-K · filed 2021-02-11 | |
| 2018-09-30 | $128.73M 10-Q · filed 2019-10-31 | $336.03M derived: sum of 2 quarters · filed 2019-10-31 | $546.21M 10-Q · filed 2019-10-31 | $646.79M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-06-30 | $207.30M 10-Q · filed 2019-08-01 | $417.46M 10-Q · filed 2019-08-01 | $518.06M derived: sum of 3 quarters · filed 2020-02-13 | $415.11M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-03-31 | $210.17M 10-Q · filed 2019-05-01 | $310.76M derived: sum of 2 quarters · filed 2020-02-13 | $207.81M derived: sum of 3 quarters · filed 2020-02-13 | $225.78M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2017-12-31 | $100.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$2.36M derived: sum of 2 quarters · filed 2020-02-13 | $15.62M derived: sum of 3 quarters · filed 2020-02-13 | $263.20M 10-K · filed 2020-02-13 | |
| 2017-09-30 | -$102.95M 10-Q · filed 2018-10-25 | -$84.98M derived: sum of 2 quarters · filed 2018-10-25 | $162.60M 10-Q · filed 2018-10-25 | $195.32M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-06-30 | $17.97M 10-Q · filed 2018-07-26 | $265.37M 10-Q · filed 2018-07-26 | $298.27M derived: sum of 3 quarters · filed 2019-02-13 | $259.43M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-03-31 | $247.35M 10-Q · filed 2018-04-27 | $280.30M derived: sum of 2 quarters · filed 2019-02-13 | $241.46M derived: sum of 3 quarters · filed 2019-02-13 | $176.93M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2016-12-31 | $32.95M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | -$5.90M derived: sum of 2 quarters · filed 2019-02-13 | -$70.42M derived: sum of 3 quarters · filed 2019-02-13 | -$112.05M 10-K · filed 2019-02-13 | |
| 2016-09-30 | -$38.84M 10-Q · filed 2017-10-30 | -$103.37M derived: sum of 2 quarters · filed 2017-10-30 | -$145.00M 10-Q · filed 2017-10-30 | ||
| 2016-06-30 | -$64.53M 10-Q · filed 2017-07-28 | -$106.16M 10-Q · filed 2017-07-28 | |||
| 2016-03-31 | -$41.63M 10-Q · filed 2017-04-28 | ||||
| 2015-12-31 | -$556.33M 10-K · filed 2018-02-15 | ||||
| 2014-12-31 | -$737.64M 10-K · filed 2015-02-13 | ||||
| 2013-12-31 | -$503.62M 10-K · filed 2015-02-13 | -$445.03M 10-K · filed 2014-02-11 | |||
| 2013-06-30 | -$57.16M 10-Q · filed 2013-08-02 | -$365.18M 10-Q · filed 2013-08-02 | -$302.34M derived: sum of 3 quarters · filed 2015-02-13 | -$359.89M derived: sum of 4 quarters · filed 2015-02-13 | |
| 2013-03-31 | -$308.02M 10-Q · filed 2013-05-08 | -$245.18M derived: sum of 2 quarters · filed 2015-02-13 | -$302.72M derived: sum of 3 quarters · filed 2015-02-13 | -$367.65M derived: sum of 4 quarters · filed 2015-02-13 | |
| 2012-12-31 | $62.84M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $5.29M derived: sum of 2 quarters · filed 2015-02-13 | -$59.64M derived: sum of 3 quarters · filed 2015-02-13 | $31.95M 10-K · filed 2015-02-13 | -$107.03M 10-K · filed 2013-03-01 |
| 2012-09-30 | -$57.54M 10-Q · filed 2012-11-06 | -$122.47M derived: sum of 2 quarters · filed 2013-08-02 | -$30.88M 10-Q · filed 2012-11-06 | $130.35M derived: sum of 4 quarters · filed 2014-02-11 | |
| 2012-06-30 | -$64.93M 10-Q · filed 2013-08-02 | $26.40M 10-Q · filed 2013-08-02 | $187.89M derived: sum of 3 quarters · filed 2014-02-11 | $410.74M derived: sum of 4 quarters · filed 2014-02-11 | |
| 2012-03-31 | $94.48M 10-Q · filed 2013-05-08 | $252.82M derived: sum of 2 quarters · filed 2014-02-11 | $475.67M derived: sum of 3 quarters · filed 2014-02-11 | $301.60M derived: sum of 4 quarters · filed 2014-02-11 | |
| 2011-12-31 | $158.34M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $381.19M derived: sum of 2 quarters · filed 2014-02-11 | $207.12M derived: sum of 3 quarters · filed 2014-02-11 | $29.29M 10-K · filed 2014-02-11 | |
| 2011-09-30 | $222.84M 10-Q · filed 2012-11-06 | $48.78M derived: sum of 2 quarters · filed 2012-11-06 | -$129.06M 10-Q · filed 2012-11-06 | -$307.71M derived: sum of 4 quarters · filed 2013-03-01 | |
| 2011-06-30 | -$174.07M 10-Q · filed 2012-08-08 | -$350.17M 10-Q · filed 2012-08-08 | -$530.56M derived: sum of 3 quarters · filed 2013-03-01 | -$739.51M derived: sum of 4 quarters · filed 2013-03-01 | |
| 2011-03-31 | -$176.10M 10-Q · filed 2012-05-10 | -$356.49M derived: sum of 2 quarters · filed 2013-03-01 | -$565.45M derived: sum of 3 quarters · filed 2013-03-01 | ||
| 2010-12-31 | -$180.39M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$389.35M derived: sum of 2 quarters · filed 2013-03-01 | -$754.63M 10-K · filed 2013-03-01 | ||
| 2010-09-30 | -$208.96M 10-Q · filed 2011-11-03 | -$574.23M 10-Q · filed 2011-11-03 | |||
| 2009-12-31 | -$642.18M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |